Science Abstracts
Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update
March 2010
March 2010
Authors : Martin Pecherstorfer
Affliation : Hematologic-Oncologic Service, Landeklinikum Krems, Mitterweg 10, A-3500 Krems, Austria ; ; martin.pecherstorfer@krems.lknoe.at
DOI : 10.1517/14656566.0.0.348462
Published in : Expert Opin. Pharmacother.
Subject:
Keywords: bisphosphonates , bone metastases , breast cancer , efficacy , ibandronic acid , intravenous , oral , safety
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- Roche tumbles after Avastin disappoints in Phase III adjuvant colon cancer trial
- Amgen's bone drug as good as Zometa in patients with solid tumours
- US panel backs Amgen's denosumab for osteoporosis treatment but not prevention
- UK does not favour centralised EU-wide assessment of clinical trials
COMMENT
Other Informa Comment
FEATURES
- Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
- Dr Jonathan Knowles: Roche's passionate visionary
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
